AbbVie is a U.S. biopharmaceutical company focused on discovering and delivering innovative medicines and solutions. It develops therapies across major disease areas and serves patients globally.
Portal Biotechnologies closes $9M funding round to expand cell engineering platform for drug discovery and cell therapy. Navikenz raises $7.5M seed round to scale AI transformation services focused on life sciences and pharmaceuticals.
A breakthrough ovarian cancer drug, mirvetuximab soravtansine, is now available on the NHS, offering extended survival and improved quality of life. The 'biological missile' therapy targets cancer cells directly, reducing side-effects compared to standard chemotherapy. Up to 400 patients in England could benefit each year.
Helus Pharma announced publication in Nature Medicine of Phase 2a trial results showing its short-acting psychedelic SPL026 met its primary endpoint with significant reductions in depressive symptoms at two weeks in moderate-to-severe MDD patients. The company also appointed a new SVP of Medical Affairs and is advancing HLP003 (Breakthrough Therapy Designation from FDA) and HLP004 in its pipeline.
A Washington federal judge declined to block a state law expanding 340B drug pricing discounts, rejecting Novartis and AbbVie's arguments that it illegally adds to their obligations under the federal program aimed at protecting low-income patients.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
The global schizophrenia drugs market is projected to grow from USD 9.1 billion in 2026 to USD 15.8 billion by 2036 at a 5.8% CAGR. Long-acting injectables and second-generation antipsychotics lead the market.
AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.
European biotechs are exploring new immunotherapy targets beyond PD-1/PD-L1, including BTLA, TIGIT, and SLAMF6. Lund University researchers discovered a SLAMF6-mediated immune evasion mechanism. BioNTech and GenMab are advancing next-generation ICIs and bispecific antibodies through strategic partnerships.
Compass Therapeutics reported mixed Phase 2/3 data for tovecimig in biliary tract cancer and plans to meet with the FDA for a BLA discussion. The study met its primary ORR endpoint (17% vs 5%), while PFS and OS data are due late this quarter.
AbbVie filed an sBLA for SKYRIZI as a subcutaneous induction therapy for Crohn's disease, supported by Phase 3 AFFIRM data. SKYRIZI and Rinvoq combined for $25.9B in 2025 revenue, exceeding 2027 guidance. The FDA also approved Venclexta plus acalabrutinib in CLL.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07607964 |
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) |
RECRUITING | PHASE1 |
| NCT07604558 |
A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants |
NOT_YET_RECRUITING | PHASE1 |
| NCT07604545 |
A Study to Assess the Use of Artificial Intellignce to Predict Eye Treatment Changes in Adult Participants With Diabetic Macular Edema |
NOT_YET_RECRUITING | |
| NCT07600762 |
A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants |
NOT_YET_RECRUITING | PHASE1 |
| NCT07600151 |
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07599761 |
A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants |
RECRUITING | PHASE1 |
| NCT07599670 |
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenous ABBV-1758 Moves Through the Body of Adult Participants With Alzheimer's Disease |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07592273 |
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema |
RECRUITING | PHASE2/PHASE3 |
| NCT07588568 |
A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07587008 |
Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy Volunteers |
NOT_YET_RECRUITING | PHASE1 |
